Horizon Europe (2021 - 2027)

Innovative Non-animal Human-based Tools and Strategies for Biomedical Research

Last update: Nov 26, 2024 Last update: Nov 26, 2024

Details

Location:EU 27
EU 27
Contracting authority type:Development Institution
Status:Awarded
Budget: EUR 25,000,000
Award ceiling: EUR 8,000,000
Award floor: EUR 4,000,000
Sector:Health, Information & Communication Technology, Science & Innovation, Research
Languages:English
Eligible applicants:Unrestricted / Unspecified
Eligible citizenships:Afghanistan, Albania, Algeria, A ...
See more
Afghanistan, Albania, Algeria, Angola, Argentina, Armenia, Aruba, Austria, Azerbaijan, Bangladesh, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Colombia, Comoros, Congo, Costa Rica, Cote d'Ivoire, Croatia, Cuba, Curaçao, Cyprus, Czech Republic, Dem. Rep. Congo, Denmark, Djibouti, Dominica, Commonwealth of, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini (Swaziland), Ethiopia, Faroe Islands, Fiji, Finland, France, French Polynesia, French Southern Territory, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Greenland, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Micronesia, Moldova, Mongolia, Montenegro, Mozambique, Myanmar, Namibia, Nepal, Netherlands, New Caledonia, Nicaragua, Niger, Nigeria, North Korea, North Macedonia, Norway, Pakistan, Palestine / West Bank & Gaza, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Romania, Rwanda, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Serbia, Sierra Leone, Slovakia, Slovenia, Spain, St. Pierre and Miquelon, Sudan, Suriname, Sweden, Syria, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Tunisia, Turkey, Turkmenistan, Tuvalu, Uganda, Ukraine, Uzbekistan, Vanuatu, Venezuela, Vietnam, Wallis and Futuna, Yemen, Zambia, Zimbabwe
Date posted: Dec 8, 2022

Attachments 3

Description

Call updates

Apr 19, 2024 5:58:16 PM

Call HORIZON-HLTH-2024-TOOL-05-two-stage has closed on 11 April 2024.

15 proposals have been submitted under topic HORIZON-HLTH-2024-TOOL-05-06-two-stage.

Evaluation results are expected to be communicated in July 2024 at the earliest.


 

Feb 13, 2024 12:22:35 PM

In order to best ensure equal treatment, successful stage 1 applicants do not receive the evaluation summary reports (ESRs) for their proposals, but this generalised feedback with information and tips for preparing the full proposal.

Information & tips

The proposals should address all the individual sub-criteria in each appropriate section of the proposal (Excellence, Impact, Implementation). E.g., the state of the art should be clearly referenced, the methodology and - where relevant – the technical robustness of AI should be clearly described, the pathways to the expected outcomes and impacts, the scale and significance of project’s contributions to the expected outcomes, and all other aspects need to be addressed.
Justify the extent of clinical testing involved. Explain how your proposal will prioritise measurable outcomes, focusing on saved lives and reduced animal use.
Outline the practical steps and considerations integral to achieving the proposed objectives to demonstrate your implementation strategies.
Multidisciplinary, social sciences and humanities (SSH) aspects must be duly considered and convincingly integrated in the methodology, particularly the harm and cost-benefit analysis. The SSH aspect is a cornerstone of this call.
If your proposal contains clinical studies, please read carefully the definition and guidance on the template ‘Information on clinical studies' published on the call page in the Participant Portal (Information on clinical studies (HE)) and remember to upload the template filled in when submitting your proposal.
In stage 2 the eligible costs will take the form of a lump sum contribution as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme. To get started, please read lump sum funding and the guide Lump sum funding - what do I need to know, with details on how to complete the Excel workbook. Recommended: Excel 2013 (Windows) / Excel 2016 (Mac OS) or more recent.
In your stage 2 proposal, you have a chance to address or clarify these issues.

Please bear in mind that your full proposal will now be evaluated more in-depth and possibly by a new group of external experts.

Please make sure that your full proposal is consistent with your short outline proposal. It may NOT differ substantially. The project must stay the same.


 

Jan 29, 2024 6:27:00 PM

In accordance with General Annex F of the Work Programme, the evaluation of the first-stage proposals was made looking only at the criteria ‘Excellence’ and ‘Impact’. The threshold for both criteria was 4. The overall threshold (applying to the sum of the two individual scores) was set at 10 points for topic HORIZON-HLTH-2024-TOOL-05-06-two-stage that allowed the total requested budget of proposals admitted to stage 2 be as close as possible to 3 times the available budget of EUR 25 000 000 (and not below 2.5 times the budget).

The results of the evaluation are as follows:
- Number of proposals submitted (including proposals transferred from or to other calls): 190
- Number of inadmissible proposals: 2
- Number of ineligible proposals: 5
- Number of above-threshold proposals: 15
- Total budget requested for above-threshold proposals: EUR 109 461 039

We recently informed the applicants about the evaluation results for their proposals.

For questions, please contact the Research Enquiry Service.

https://research-and-innovation.ec.europa.eu/contact-us/research-enquiry-service_en


 

Sep 20, 2023 6:47:09 PM

First stage of call HORIZON-HLTH-2024-TOOL-05-two-stage closed on 19 September 2023. 190 proposals were submitted. The breakdown per topic is:

HORIZON-HLTH-2024-TOOL-05-06-two-stage: 190 proposals
Evaluation results are expected to be communicated on 24 January 2024 at the earliest.


Mar 31, 2023 11:22:04 AM

The submission session is now available for: HORIZON-HLTH-2024-TOOL-05-06-two-stage(HORIZON-RIA)


Innovative non-animal human-based tools and strategies for biomedical research

TOPIC ID: HORIZON-HLTH-2024-TOOL-05-06-two-stage

Programme: Horizon Europe Framework Programme (HORIZON)
Call: Tools and technologies for a healthy society (Two stage - 2024) (HORIZON-HLTH-2024-TOOL-05-two-stage)
Type of action: HORIZON-RIA HORIZON Research and Innovation Actions
Type of MGA: HORIZON Lump Sum Grant [HORIZON-AG-LS]
Deadline model: two-stage
Planned opening date: 30 March 2023
Deadline dates: 19 September 2023 17:00:00 Brussels time
11 April 2024 17:00:00 Brussels time

Topic description
 
ExpectedOutcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following Expected Outcomes:

  • Researchers utilise tools and strategies that are more relevant to the human situation as compared to the currently used animal models.
  • Fewer live animals are used in biomedical research.
  • Health technology developers will get access to improved human-relevant tools or strategies allowing for a faster pace of innovation.
  • Legislators and regulators will benefit from strengthened EU leadership in non-animal based biomedical research that is socially accepted and sustainable.
  • Healthcare providers and patients will benefit from innovative tools or strategies opening up novel biomedical concepts enabling improved disease prediction, prevention and treatment.
Scope:

The proposal(s) should develop and/or use tools and strategies that address critical areas of biomedical research where animal-models are currently used but are of limited translational value for investigation and development of prevention and treatment. Such advanced tools and strategies should aim at a better understanding of the pathogenesis of disorders that feature a high impact on public health and exhibit a high rate of animal use or severe animal suffering, and enable to develop biomedical concepts with increased translational value, thereby ultimately leading to improved disease prediction, prevention and treatment.

The proposals should address all of the following aspects:

  • The innovative tools and strategies should include a variety of technologies and methodological approaches such as –omics and other high-throughput procedures, human-derived cell-based material, organoids, micro-physiological systems, and in-silico models.
  • The newly proposed tools and strategies should demonstrably advance the state-of-the-art in specific areas of biomedical research.
  • Prospects and avenues for dissemination, knowledge sharing, uptake or translation into health policies of the proposed tools and strategies within the EU should be provided.
  • Aspects such as harm and cost-benefit assessment as well as ease of production with respect to current practices should also be considered.
  • Criteria for model qualification and standardisation should be developed in well-justified use-case contexts to demonstrate their translational values.

Proposals could consider the involvement of the European Commission's Joint Research Centre (JRC) to provide added-value regarding such aspects as supporting validation of emerging approaches, promotion of research results, and the interfacing with the regulatory community. In this respect, the JRC is open to collaborate with any successful proposal after the selection process has been completed.

All projects funded under this topic are strongly encouraged to participate in networking and joint activities. These networking and joint activities could, for example, involve the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Therefore, proposals are expected to include a budget for the attendance to regular joint meetings and may consider covering the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase. In this regard, the Commission may take on the role of facilitator for networking and exchanges, including with relevant stakeholders.

This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

Applicants invited to the second stage and envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.

 
 
 
Want to unlock full information?
Member-only information. Become a member to access this information. Procurement notices from over 112+ donors and banks are available here